On the stock market since 2017, it operates in the world of health and science. Now — the numbers.
The stock trades below its recent peak — about 9% off the top. A pullback, not a collapse.
It pays out $0.0012 per share each year — regular cash for whoever holds the stock.
The stock sits at $0.15. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, PSTTF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PSTTF is a high-risk stock — not yet profitable, and its future rides on its product catching on.